What is the recommended treatment regimen for typical absence seizures in children, including first-line medication and dosing?

Treatment of Typical Absence Seizures in Children

Ethosuximide is the optimal first-line treatment for typical absence seizures in children when absence seizures occur alone, based on superior efficacy and tolerability compared to other antiseizure medications 1, 2.

First-Line Medication Selection

For Absence Seizures Only

• Ethosuximide is the treatment of choice
  • Initial dose: 0.5 mg/kg/day for 2 weeks 3
  • Titrate to 1.0 mg/kg/day for an additional 2 weeks
  • Increase in 1 mg/kg/day increments up to 9-12 mg/kg/day based on clinical response 3
  • Controls absences in approximately 70% of patients 4
  • Critical limitation: Ineffective against generalized tonic-clonic seizures (GTCS), so unsuitable if both seizure types coexist 1, 4

For Absence Seizures Plus GTCS

• Valproic acid (VPA) should be preferred when absence and GTCS coexist 1, 2
  • Controls absences in 75% of patients 4
  • Also controls GTCS in 70% and myoclonic jerks in 75% 4
  • Major caveat: Avoid in women of childbearing potential due to teratogenicity and cognitive effects 5
  • Higher rate of intolerable adverse events compared to ethosuximide 1

Alternative First-Line Option

• Lamotrigine is less effective than ethosuximide or VPA 1
  • Significantly higher treatment failure rate due to lack of seizure control 1
  • May control absences and GTCS in 50-60% of patients 4
  • Important warning: May worsen myoclonic jerks 6, 4
  • Slow titration required (risk of serious rash including Stevens-Johnson syndrome) 6, 3
  • Initial dose: 0.5 mg/kg/day for 2 weeks, then 1.0 mg/kg/day for 2 weeks, titrate to 1-5 mg/kg/day with enzyme inducers or 1-3 mg/kg/day with VPA 6

Evidence Quality

The recommendation hierarchy is based on a large, high-quality randomized controlled trial 1 that directly compared all three medications in children with newly diagnosed childhood absence epilepsy. This study demonstrated:

• Freedom-from-failure rates at 12 months were similar for ethosuximide and VPA, both significantly higher than lamotrigine
• Lamotrigine had the highest proportion of treatment failures due to lack of seizure control
• VPA had the highest proportion of intolerable adverse events
• Ethosuximide provided optimal balance of efficacy and tolerability

Refractory Cases (20-30% of patients)

When monotherapy with ethosuximide, VPA, or lamotrigine fails 7:

1. Combination therapy: Low-dose lamotrigine added to VPA may have dramatic beneficial effect 4
2. Alternative adjunctive options:
   • Clonazepam (particularly for absences with myoclonic components) 4
   • Acetazolamide 4
   • Levetiracetam, topiramate, or zonisamide (limited evidence) 5

Critical consideration: Before escalating therapy in refractory cases, rule out glucose transporter type 1 (GLUT1) deficiency, especially if absences started before age 4 years or neurological signs are present 7. Also exclude pseudo-drug resistance (non-compliance, incorrect diagnosis).

Common Pitfalls

• Do not use ethosuximide if patient has both absence and GTCS—it will not control the GTCS 1
• Avoid gabapentin in generalized epilepsies—may worsen myoclonic seizures 6
• Prioritize limiting cognitive side effects over achieving complete seizure freedom in refractory cases, as evidence that seizure control improves cognitive deficits is weak 7
• Remember slow lamotrigine titration to minimize rash risk, which may reduce compliance 3